<DOC>
	<DOC>NCT01197911</DOC>
	<brief_summary>This open-label study will assess the effects of hepatic impairment on the pharmacokinetics of a single oral dose of aleglitazar in subjects with mild or moderate hepatic impairment (Child-Pugh class A or B) and in matched control subjects with normal hepatic function. Subjects will receive a single oral dose of aleglitazar, with assessment of the pharmacokinetics of aleglitazar on Days 1-5. Anticipated duration of study for each enrolled subject is approximately 6 weeks.</brief_summary>
	<brief_title>A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar</brief_title>
	<detailed_description />
	<criteria>Male and female adults, 1870 years of age inclusive Normal hepatic function or mild to moderate impaired liver function (ChildPugh class A or B) Body mass index (BMI) 18 to 40 kg/m2 inclusive Females must be either surgically sterile, postmenopausal, or willing to use two reliable methods of contraception for the duration of the study and started 3 months before study start For subjects with hepatic impairment: evidence of progressive liver disease within the last 4 weeks, or biliary liver cirrhosis or other causes of hepatic impairment not related to parenchymal disorder and/or disease For healthy volunteers: positive test for hepatitis B or C, alcohol intake of more than 14 units per week, or history of clinically significant alcohol or drug abuse Acute infection or current malignancy requiring treatment History of clinically significant allergic disease or drug hypersensitivity Positive test for HIV1 or HIV2 at screening Participation in a clinical study with an investigational drug or new chemical entity within 2 months prior to screening Females who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>